144 related articles for article (PubMed ID: 14567371)
1. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States.
Majumdar SR; McAlister FA; Soumerai SB
Am J Med; 2003 Oct; 115(6):467-72. PubMed ID: 14567371
[TBL] [Abstract][Full Text] [Related]
2. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
[TBL] [Abstract][Full Text] [Related]
3. HOPE study impact on ACE inhibitors use.
Hemels ME; Bennett HA; Bonari L; Han D; Traverso ML; Einarson TR
Ann Pharmacother; 2003 May; 37(5):640-5. PubMed ID: 12708937
[TBL] [Abstract][Full Text] [Related]
4. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative.
Majumdar SR; Almasi EA; Stafford RS
JAMA; 2004 Oct; 292(16):1983-8. PubMed ID: 15507584
[TBL] [Abstract][Full Text] [Related]
5. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
Lamy A; Yusuf S; Pogue J; Gafni A;
Circulation; 2003 Feb; 107(7):960-5. PubMed ID: 12600907
[TBL] [Abstract][Full Text] [Related]
6. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario.
Tu K; Mamdani MM; Jacka RM; Forde NJ; Rothwell DM; Tu JV
CMAJ; 2003 Mar; 168(5):553-7. PubMed ID: 12615747
[TBL] [Abstract][Full Text] [Related]
7. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).
Hauben M; Reich L; Gerrits CM; Madigan D
Drug Saf; 2007; 30(12):1143-9. PubMed ID: 18035866
[TBL] [Abstract][Full Text] [Related]
8. Impact of ALLHAT publication on antihypertensive prescribing patterns in Regione Emilia-Romagna, Italy.
Maio V; Gagne JJ
J Clin Pharm Ther; 2010 Feb; 35(1):55-61. PubMed ID: 20175812
[TBL] [Abstract][Full Text] [Related]
9. Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence.
Datta A; Dave D
Health Econ; 2017 Apr; 26(4):450-468. PubMed ID: 26893065
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study.
Siriwardena AN; Fairchild P; Gibson S; Sach T; Dewey M
Fam Pract; 2007 Feb; 24(1):26-33. PubMed ID: 17052988
[TBL] [Abstract][Full Text] [Related]
11. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.
Stafford RS; Furberg CD; Finkelstein SN; Cockburn IM; Alehegn T; Ma J
JAMA; 2004 Jan; 291(1):54-62. PubMed ID: 14709576
[TBL] [Abstract][Full Text] [Related]
12. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States.
Stafford RS; Monti V; Furberg CD; Ma J
Hypertension; 2006 Aug; 48(2):213-8. PubMed ID: 16785334
[TBL] [Abstract][Full Text] [Related]
13. Economic implications of treatment guidelines for congestive heart failure.
Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
[TBL] [Abstract][Full Text] [Related]
14. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
[TBL] [Abstract][Full Text] [Related]
15. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
16. [Effects of the RALE study. Hyperkalemia following spironolactone treatment].
Erdmann E
Internist (Berl); 2005 Apr; 46(4):466, 468. PubMed ID: 15723149
[No Abstract] [Full Text] [Related]
17. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.
Kizer JR; Cannon CP; McCabe CH; Mueller HS; Schweiger MJ; Davis VG; Perritt R; Antman EM
Am Heart J; 1999 Jan; 137(1):79-92. PubMed ID: 9878939
[TBL] [Abstract][Full Text] [Related]
18. Ramipril for the prevention and treatment of cardiovascular disease.
Vuong AD; Annis LG
Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
[TBL] [Abstract][Full Text] [Related]
19. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
20. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
Grover SA; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
